Videos

Risa Wong, MD, discusses the sequencing of treatments in the metastatic urothelial carcinoma armamentarium, including chemotherapy, immune checkpoint inhibitors, and antibody-drug conjugates.

Although women represent an increasing percentage of the urology workforce, they continue to be underrepresented in receiving recognition awards from the American Urological Association.

"I think [at] the 2021 ASCO annual meeting, we saw a lot of novel data focusing on bladder-preservation approaches," says Shilpa Gupta, MD.

Miron presented a study at the 2021 ASCO Annual Meeting that explored the influence of first-line chemotherapy choice on survival outcomes in patients who received immunotherapy in the second-line setting.

In this video, Shilpa Gupta, MD, discusses the rapidly evolving world of research on urothelial carcinoma.

Miron et al specifically compared the choice between frontline cisplatin plus gemcitabine versus frontline carboplatin plus gemcitabine in patients with advanced urothelial carcinoma.

“There are a couple of different important and unique questions that expert witnesses help answer in the context of medical malpractice litigation,” says Kenton H. Steele, Esq.

Seideman says urology is a great option for women considering a surgical subspecialty.

Dr. Neal D. Shore discusses multidisciplinary care in prostate cancer against the backdrop of the ODENZA trial, which assessed patient preference between darolutamide and enzalutamide.

Ranjith Ramasamy, MD, comments on SOV2012-F1 (Kyzatrex), an oral testosterone undecanoate soft gelatin capsule.

“If we allow a cardiologist to be critical of a family medicine practitioner, there's a chance that they're being held to an unreasonable standard that doesn't apply to their day to day, which is why that requirement is in place for most but not all states,” says Kenton H. Steele Esq.

Although women represent an increasing percentage of the urology workforce, they remain underrepresented in receiving recognition awards from the American Urological Association.

Expert urologists remark on unmet needs in prostate cancer by emphasizing the importance of reaching under-served communities, addressing patient discomfort, increasing education about liquid biopsy testing, and standardizing prostate size assessment.

Kyle Wood, MD, provides insight on the types of hyperoxaluria, the importance of disease education, and who should be screened for the disease.

"I do think there's a big opportunity, if [telemedicine is] used correctly, to overcome some of these workforce shortages," says Chad Ellimoottil, MD, MS.

Casey Seideman, MD, discusses the gender pay gap in urology and the path forward to address the issue.

Health care providers focus on genomic testing in heavily treated, metastatic castrate-resistant prostate cancer from the multidisciplinary approach to cancer care.

Health care providers focus on genomic testing in newly diagnosed, high grade, high-risk prostate cancer from the multidisciplinary approach to cancer care.

A recently published study showed an increased risk of cardiac failure in men with BPH and exposure to 5-alpha reductase inhibitors and/or α-blockers.

“We found that medications allegedly causing priapism and the litigation surrounding that is significant because it means that the patient-physician relationship was not well established,” says Ariana Matz, MD.

Robert J. Motzer, MD, discusses health-related quality of life analyses from the phase 3 CLEAR trial of frontline pembrolizumab plus lenvatinib in patients with metastatic renal cell carcinoma.

The UroLift System is a noninvasive treatment for patients with BPH that relieves prostate obstruction by lifting and holding the prostate tissue that is blocking the urethra.

In this interview, Amy M. Pearlman, MD, also discusses how she uses social media at professional conferences.

Key opinion leaders in urology review factors to consider when selecting screening and risk-assessment tests for the diagnosis of prostate cancer including insurance coverage, commercial availability, and patient preference.

“While patient facing apps hold great potential to support self-management behaviors, particularly in stone disease, thoughtful consideration across an array of domains should really be taken prior to supporting or even recommending one of these apps to a patient,” says Jared S. Winoker, MD.

David Albala, MD and Judd W. Moul, MD consider the impact that COVID-19 has had on the clinical experience of patients with prostate cancer and share personal insights regarding telehealth and patient compliance.

In an interview conducted during the 2021 ASCO Annual Meeting, Robert A. Figlin, MD, deputy director, Cedars-Sinai Cancer, shared his expertise on trends in the treatment of patients with genitourinary cancers.

“It's quick to act and it's quick to leave the system,” says Ranjith Ramasamy, MD, of the nasal testosterone gel Natesto.

In the phase 3 VISION trial, adding the targeted radioligand therapy 177Lu-PSMA-617 to standard of care led to a nearly 40% reduction in the risk of death.

Nearly half of the surveyed men reported that urinary symptoms led them to avoid events or activities they enjoy.